Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey.
作者： Per Soelberg Sorensen , Nils Koch-Henriksen , Mads Ravnborg , Jette Lautrup Frederiksen , K ai Jensen
DOI: 10.1191/135248506MS1323OA
关键词: Multiple sclerosis 、 Internal medicine 、 Population 、 Adverse effect 、 Hazard ratio 、 Epidemiology 、 Medicine 、 Neurological examination 、 Proportional hazards model 、 Surgery 、 Expanded Disability Status Scale
摘要: Objective: The aim of the present study was to provide data on use immunomodulatory therapies in a population comprising all treated patients with relapsing-remitting multiple sclerosis (RRMS) Denmark. Patients and methods: From introduction therapy Denmark 1996 through 2003, that started were followed prospectively neurological examination standard laboratory tests every six months, clinical reported MS Treatment Register, including relapses, Expanded Disability Status Scale scores side effects. Results: 2003 2393 had for RRMS, whom 1252 (52.3%) still same product at follow-up 1 January 2005, whereas 1141 discontinued or changed therapy. Multiple Cox regression analysis risk suffering relapse showed hazard ratio 1.48 three more rela...
core.ac.uk
sagepub.com
sci-hub.se 参考文章(19)
Maria Trojano, Maria Liguori, Damiano Paolicelli, Giovanni Bosco Zimatore, Francesca De Robertis, Carlo Avolio, Fabrizio Giuliani, Aurora Fuiani, Paolo Livrea, , Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Multiple Sclerosis Journal. ,vol. 9, pp. 451- 457 ,(2003) , 10.1191/1352458503MS948OA
K. P. Johnson, B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, R. B. Schiffer, T. Vollmer, L. P. Weiner, J. S. Wolinsky, , Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis Results of a phase III multicenter, double‐blind, placebo‐controlled trial Neurology. ,vol. 45, pp. 1268- 1276 ,(1995) , 10.1212/WNL.45.7.1268
Nils Koch-Henriksen, Per Soelberg Sùrensen, , The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis Multiple Sclerosis Journal. ,vol. 6, pp. 172- 175 ,(2000) , 10.1177/135245850000600306
A. Paolillo, C. Pozzilli, E. Giugni, V. Tomassini, C. Gasperini, M. Fiorelli, C. Mainero, M. Horsfield, S. Galgani, S. Bastianello, C. Buttinelli, A 6-year clinical and MRI follow-up study of patients with relapsing–remitting multiple sclerosis treated with Interferon-beta European Journal of Neurology. ,vol. 9, pp. 645- 655 ,(2002) , 10.1046/J.1468-1331.2002.00476.X
J. Haas, M. Firzlaff, Twenty‐four‐month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®) European Journal of Neurology. ,vol. 12, pp. 425- 431 ,(2005) , 10.1111/J.1468-1331.2005.00936.X
Giancarlo Comi, Massimo Filippi, Frederik Barkhof, Luca Durelli, Gilles Edan, Oscar Fernández, Hans-Peter Hartung, Pierrette Seeldrayers, Per Soelberg Sørensen, Marco Rovaris, Vittorio Martinelli, Otto R Hommes, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. The Lancet. ,vol. 357, pp. 1576- 1582 ,(2001) , 10.1016/S0140-6736(00)04725-5
Per Soelberg Sorensen, Christian Ross, Katja Maria Clemmesen, Klaus Bendtzen, Jette Lautrup Frederiksen, Kai Jensen, Ole Kristensen, Thor Petersen, Soren Rasmussen, Mads Ravnborg, Egon Stenager, Nils Koch-Henriksen, Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. The Lancet. ,vol. 362, pp. 1184- 1191 ,(2003) , 10.1016/S0140-6736(03)14541-2
W. Ian McDonald, Alistair Compston, Gilles Edan, Donald Goodkin, Hans-Peter Hartung, Fred D. Lublin, Henry F. McFarland, Donald W. Paty, Chris H. Polman, Stephen C. Reingold, Magnhild Sandberg-Wollheim, William Sibley, Alan Thompson, Stanley Van Den Noort, Brian Y. Weinshenker, Jerry S. Wolinsky, Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis Annals of Neurology. ,vol. 50, pp. 121- 127 ,(2001) , 10.1002/ANA.1032
Frederik Barkhof, Massimo Filippi, David H Miller, Philip Scheltens, Adriana Campi, Chris H Polman, Giancarlo Comi, Herman J Ader, Nick Losseff, Jacob Valk, Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. ,vol. 120, pp. 2059- 2069 ,(1997) , 10.1093/BRAIN/120.11.2059
C Milanese, A post-marketing study on interferon 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients Journal of Neurology, Neurosurgery & Psychiatry. ,vol. 74, pp. 1689- 1692 ,(2003) , 10.1136/JNNP.74.12.1689